

ASX ANNOUNCEMENT

29 March 2021

OUTSTANDING PERFORMANCE OF ANTERIS' ADAPT[®] ANTI-CALCIFICATION TECHNOLOGY IN HEAD TO HEAD STUDY AGAINST AOA[™]

Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR; **Anteris** or the **Company**) reports results from the Company's anti-calcification study indicating its ADAPT[®] treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.

Results showed the ADAPT[®] treated tissue – used in the DurAVR[™] 3D single-piece aortic valve – had approximately **38%** less calcium concentration compared with the Medtronic AOA[™] porcine arm – the tissue used in commercially available TAVR Valves – and 26% less calcium in the bovine arm. Bovine tissue is used in some of the Medtronic SAVR (surgical aortic valve replacement) valves.

Using a well-established rat model to determine if different anti-calcification methods are likely to have clinical relevance, four tissue samples (ADAPT[®], AOA[™] Porcine, AOA[™] Bovine and control= GA treated bovine pericardium) were implanted subcutaneously in each rat (n=48). The animals were sacrificed at four and eight months after implantation and tissue samples were analysed histologically as well as for calcium per tissue weight.

The geometric mean calcium content for ADAPT[®] was highly significantly less than the geometric mean for AOA[™] Bovine (GMR = 0.74, 95% CI = (0.59, 0.92), P = 0.007) and highly significantly less for AOA[™] Porcine (GMR = 0.62, 95% CI = (0.50, 0.78), P < 0.001). For calcium the geometric mean for ADAPT[®] was 26% (95% CI = 8%, 41%) less than the GM for AOA[™] Bovine, and 38% (95% CI = 22%, 50%) less than the GM for AOA[™] Porcine.

"The geometric mean ratios demonstrated clear separation between the 95% CI and 1.0, thus confirming the highly significant reduction of calcium for the ADAPT[®] arm compared to the AOA[™] Bovine arm (P = 0.007), and AOA[™] Porcine arm (P < 0.001)," Dr Phillip McCloud of McCloud Consulting Group, a renowned biostatistician who performed an independent review of these data, said.

The results correlated with existing clinical data and those of the prior head-to-head study with a similar protocol which produced significant differentials between ADAPT[®] tissue and Edwards Life Sciences' Thermafix[™] tissue at the eight to 12-month mark.

"These findings clearly demonstrated the superior performance of the ADAPT[®] tissue engineered process as an anti-calcification technology against some of the top competitors in the marketplace. It further supports previous human studies and clinical experience demonstrating ADAPT[®] has a clinically relevant profile in terms of resisting calcification," Anteris Chief Executive Officer, Mr Wayne Paterson, said.

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



For personal use only

Calcification (hardening) is a significant contributor to the failure of heart valve replacements made from animal tissue. There is an imperative for better anti-calcification treatments such as ADAPT[®] to help ensure replacement heart valves last longer and work better.

Based on these encouraging results, the Company plans to undertake a further study comparing the ADAPT[®] anti-calcification treatment in a head to head study with both Medtronic's AOA[™] and the next generation TAVR tissue treatment, Resilia[®], from Edwards Lifesciences.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR[™] aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR[™]'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech